evaluate the effectiveness of crosslinked ha on the adhesion preventing after trigger finger release surgery

Conditions: Trigger Finger; Hyaluronic Acid

Summary: to evaluate the effectiveness of the use of a novel crosslinking hyaluronan hydrogel on the prevention of the adhesion occurrence after trigger finger release surgery

the medical device is a bioabsorbable, extensible, crosslinked, 6% hyaluronic acid gel using fermentation sourced hyaluronic acid as a major component. this product could perfectly attach to the tissue surface, creating anti-adhesion layer which avoids post-surgical adhesion and is completely resorbed over time. this study is aimed to evaluate the effectiveness of the use of a novel crosslinking hyaluronan hydrogel on the prevention of the adhesion occurrence after trigger finger release surgery.

Eligibility criteria:
inclusion criteria: 1. agree to participate in this study and sign informed consent form 2. age 20 to 65 years of male or female 3. the trigger finger, except thumb, classified as 3 to 4 points and plan to conduct trigger finger release surgery; 4. the trigger finger, except thumb, classified as 2 points with the symptom of flexion contracture and plan to conduct trigger finger release surgery; 5. agree to comply with the follow-up schedule of this study exclusion criteria: 1. target finger has other adhesion in tendon, joint, or proximal nerve, neuropathy, compression injury or other disease; 2. other fingers in the same hand as the target finger have other adhesion in tendon, joint, or proximal nerve, neuropathy, or compression injury; 3. contralateral finger has other adhesion in tendon, joint, or proximal nerve, neuropathy, or compression injury; 4. the operation site was conducted tendon transplantation or any surgery in past 6 months; 5. receiving orthopedic-related treatment which may affect the evaluation of the study; 6. the skin of the operation site with infection, deficiency, or needing skin transplantation; 7. with poorly controlled chronic diseases, such as diabetes mellitus; 8. patient with autoimmune disease (such as rheumatoid arthritis), malignant tumors, coagulation diseases, heart diseases, mental diseases, etc., may cause patients to participate in the trial at higher risk; 9. patient who has taken cortisol within the past 6 months, systemic corticosteroids within the past 2 months, immunosuppressive drugs within past 3 months, or non-steroidal anti-inflammatory drugs (nsaids) everyday within 1 week or nsaids within 8 hours occasionally. (subjects who have received inhaled/intranasal corticosteroids could be considered to include.); 10. with clinical meaningful coagulation disorders, underdoing anticoagulant treatment or taking blood circulation promotion and blood stasis removement medications within the past 10 days; 11. with history of hypersensitivity or allergy to hyaluronic acid or any component of the device; with history of hypersensitivity or allergy to gram-positive bacteria or streptococcus proteins; other severe hypersensitivity history unsuitable for participating in the study; 12. pregnant, planning pregnancy or in breastfeeding females; 13. other circumstances which judged to be unsuitable for participating in the study by the investigator.